C. Frank Bennett
C. Frank Bennett (* 1960 ) is an American pharmacologist.
Bennett holds a bachelor's degree in pharmacology from the University of New Mexico and a PhD in pharmacology from the University of Texas's Baylor College of Medicine . He conducted research for SmithKline and French Laboratories and was a co-founder of Ionis Pharmaceuticals in Carlsbad, California in 2006 , where he is Senior Vice President of Research.
He develops drugs based on antisense oligonucleotides (ASO) specifically for neurodegenerative diseases such as Parkinson's disease and cancer chemotherapy. In particular, he was able to show in monkeys that by injecting the ASOs into the spinal cord fluid, the ASOs could cross the blood-brain barrier and spread well into the cortex and other brain regions. The expression of the target gene could be reduced by half on average. Bennett holds around 150 US patents.
For 2019 he received the Breakthrough Prize in Life Sciences with Adrian R. Krainer , with whom he also worked.
He advises the Experimental Therapeutics Center in Singapore and is on the advisory board of the American Society of Gene and Cell Therapy.
Web links
Individual evidence
- ^ Wall Street Journal , Executive Profile Ionis Pharmaceuticals 2018
- ↑ At AAN, Sights Set on Antisense Therapies for Diseases of the Brain , Alzforum, report on the annual meeting of the American Academy of Neurology in April 2018
| personal data | |
|---|---|
| SURNAME | Bennett, C. Frank |
| BRIEF DESCRIPTION | American pharmacologist |
| DATE OF BIRTH | 1960 |